Breaking News Instant updates and real-time market news.

AMRN

Amarin

$16.59

0.42 (2.60%)

10:05
02/08/19
02/08
10:05
02/08/19
10:05

Amarin call volume above normal and directionally bullish

Bullish option flow detected in Amarin with 4,470 calls trading, 1.1x expected, and implied vol increasing over 5 points to 87.72%. Feb-19 16.5 calls and 2/8 weekly 17 calls are the most active options, with total volume in those strikes near 2,400 contracts. The Put/Call Ratio is 0.10. Earnings are expected on February 26th.

AMRN Amarin
$16.59

0.42 (2.60%)

01/08/19
SBSH
01/08/19
NO CHANGE
Target $20
SBSH
Buy
Amarin price target lowered to $20 from $28 at Citi
Citi analyst Joel Beatty lowered his price target for Amarin to $20 after the company's 2019 revenue guidance came in lower than he expected. The analyst, however, continues to view Vascepa as an "attractive and differentiated cardiovascular risk reduction therapy." His peak sales estimate is now $2.5B, down from $3.0B previously.
01/17/19
HCWC
01/17/19
NO CHANGE
Target $51
HCWC
Buy
H.C. Wainwright reiterates $51 price target on Amarin shares
H.C. Wainwright analyst Andrew Fein reiterates an Buy rating on Amarin with a $51 price target after hosting a meeting with management during the JPMorgan Healthcare conference. Management noted that the majority of physician feedback post American Heart Association was positive towards Vascepa, Fein tells investors in a research note.
01/31/19
CANT
01/31/19
NO CHANGE
Target $35
CANT
Overweight
Cantor reiterates $35 target on Amarin after surveying 50 physicians
After surveying 50 physicians regarding Vascepa, Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Amarin with a $35 price target. The stock closed yesterday up 48c to $16.94. The analyst says the survey results underscore her belief that the market opportunity is underappreciated. 52% of physicians noted the high triglyceride patients they see have cardiovascular risk factors beyond what can be mitigated by cholesterol management, Chen tells investors in a research note. She believes the Reduce-It study positions Vascepa to be the first drug to cost-effectively help address CV risk beyond cholesterol management. Chen expects an acceleration in the uptake of Vascepa in 2019.
02/01/19
PIPR
02/01/19
NO CHANGE
PIPR
Overweight
Amgen acquisition of Alexion could make a lot of sense, says Piper Jaffray
While most investors anticipate Amgen (AMGN) could be shopping for smaller, bolt-on deals amid increased investor and press speculation that it is now an active acquirer, a larger deal with more near-term accretion potential may make more sense, Piper Jaffray analyst Christopher Raymond tells investors in a research note partially titled "Go Big or Go Home?" He thinks a potential Amgen for Alexion Pharmaceuticals (ALXN) deal "could actually make a lot of sense." Even at levels approaching $200 per share for Alexion, Amgen "could make a strong argument for a business combination," says Raymond. Alexion closed yesterday up $1.64 to $122.96. The analyst admits that some "bolt-on deals have been bandied around" by investors that "arguably make sense" for Amgen, including Biohaven Pharmaceutical and Amarin (AMRN). However, none of these options on their own get Amgen "to where they need to be to address the growth challenges of the legacy franchises," Raymond argues. He thinks a better deal for the company may be Alexion, which would bring in a "long-tailed asset" with Soliris/Ultomiris, an area Amgen has already approached with its Soliris biosimilar effort. The analyst's math has the potential deal being accretive next year, growing to 20%-plus accretion by 2024 for Amgen, even at a takeout price approaching $200 per Alexion share. Raymond keeps Overweight ratings on both companies.

TODAY'S FREE FLY STORIES

LCI

Lannett

$7.82

-0.61 (-7.24%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Lannett falls -5.1% »

Lannett is down -5.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NL

NL Industries

$4.80

(0.00%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
NL Industries falls -6.6% »

NL Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JE

Just Energy

$3.94

-0.44 (-10.05%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Just Energy falls -11.4% »

Just Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PII

Polaris Industries

$87.80

5.265 (6.38%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Polaris Industries rises 6.4% »

Polaris Industries is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EDU

New Oriental Education

$104.82

6.585 (6.70%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
New Oriental Education rises 6.4% »

New Oriental Education is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RLGY

Realogy

$6.61

1.44 (27.85%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Realogy rises 28.2% »

Realogy is up 28.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

MGLN

Magellan Health

$68.15

(0.00%)

09:46
07/23/19
07/23
09:46
07/23/19
09:46
Periodicals
Magellan Health talks with Centerbridge hung up on price, Dealreporter says »

Centerbridge Partners and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$33.01

-1.24 (-3.62%)

09:45
07/23/19
07/23
09:45
07/23/19
09:45
Hot Stocks
Harley-Davidson CEO says profit margins to recover in FY20 with fixed EU tariffs »

Harley-Davidson CEO Matt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

09:45
07/23/19
07/23
09:45
07/23/19
09:45
General news
Richmond Fed Manufacturing Index Level to be reported at 10:00 »

July Richmond Fed…

09:45
07/23/19
07/23
09:45
07/23/19
09:45
General news
Existing Home Sales to be reported at 10:00 »

June Existing Home Sales…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Hot Stocks
FDA sends warning letter to Curaleaf over unapproved, 'misbranded' drugs »

The FDA posted on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$79.54

(0.00%)

, SHLAF

Schindler

$0.00

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Hot Stocks
Eaton appoints Silvio Napoli to board of directors »

Eaton (ETN) announced…

ETN

Eaton

$79.54

(0.00%)

SHLAF

Schindler

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

AZN

AstraZeneca

$40.32

(0.00%)

, GM

General Motors

$39.86

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Options
Unusually active option classes on open July 23rd »

Unusual total active…

AZN

AstraZeneca

$40.32

(0.00%)

GM

General Motors

$39.86

(0.00%)

WHR

Whirlpool

$148.30

(0.00%)

HAS

Hasbro

$108.54

(0.00%)

KO

Coca-Cola

$51.25

(0.00%)

BIIB

Biogen

$232.46

(0.00%)

LMT

Lockheed Martin

$357.57

(0.00%)

ABT

Abbott

$88.08

(0.00%)

BYND

Beyond Meat

$193.91

(0.00%)

NVDA

Nvidia

$171.32

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 29

    Jul

  • 01

    Aug

  • 03

    Aug

  • 12

    Aug

  • 15

    Aug

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 25

    Sep

  • 02

    Oct

  • 23

    Oct

09:40
07/23/19
07/23
09:40
07/23/19
09:40
General news
U.S. existing home sales preview: analysts expect a steady rate for June existing home sales »

U.S. existing home sales…

CABO

Cable One

$1,206.29

-11.71 (-0.96%)

09:38
07/23/19
07/23
09:38
07/23/19
09:38
Upgrade
Cable One rating change at Wolfe Research »

Cable One upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFSF

MutualFirst Financial

$32.20

0.28 (0.88%)

09:37
07/23/19
07/23
09:37
07/23/19
09:37
Earnings
MutualFirst Financial reports Q2 EPS 66c, consensus 62c »

The Company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$6.22

-0.38 (-5.76%)

09:35
07/23/19
07/23
09:35
07/23/19
09:35
Hot Stocks
CEL-SCI announces review published in International Immunopharmacology »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$132.94

0.57 (0.43%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Hot Stocks
United Technologies says 'very confident' about updated FY19 guidance »

Says: More good things to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PKX

Posco

$49.91

-0.26 (-0.52%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Upgrade
Posco rating change at Macquarie »

Posco upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

TRPX

Therapix Biosciences

$2.32

-0.02 (-0.85%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Hot Stocks
Therapix Biosciences signs LOI to merge with Destiny Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

09:32
07/23/19
07/23
09:32
07/23/19
09:32
Recommendations
Amazon.com analyst commentary at BMO Capital »

Amazon.com Q3 consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UGP

Ultrapar

$5.23

-0.165 (-3.06%)

09:32
07/23/19
07/23
09:32
07/23/19
09:32
Upgrade
Ultrapar rating change at Bradesco »

Ultrapar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

09:31
07/23/19
07/23
09:31
07/23/19
09:31
Hot Stocks
Breaking Hot Stocks news story on Harley-Davidson »

Harley-Davidson sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SEMG

SemGroup

$11.92

0.13 (1.10%)

09:31
07/23/19
07/23
09:31
07/23/19
09:31
Upgrade
SemGroup rating change at Citi »

SemGroup upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

09:28
07/23/19
07/23
09:28
07/23/19
09:28
Hot Stocks
Harley-Davidson continues to see FY19 annual cash savings of $25M-$30M »

Sees FY20 annual cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.